Tenofovir disoproxil fumarate in the treatment of COVID-19: Evaluation of 78 patients
Makaleler > Tam Makale · 2024
Yazarlar: Gamze Sanlidag Isbilen, Isabel Raika Durusoy Onmu, Ilkin Cankayali, Kubilay Demira, Mehmet Uyar, Candan Cicek, Tansu Yamazhan, Huesnue Pullukcu, Oğuz Reşat SİPAHİ
NEW MICROBIOLOGICA, SCI İndekslerine Giren Dergi, Uluslararası, Wos, 2024, cilt 47, ss 47-51
Özet
One of the drugs that has been suggested for the treatment of SARS-CoV-2 infection is tenofovir disoproxil (TDF). Herein, it was aimed to evaluate the outcomes of TDF receiving COVID-19 cases in terms of day 7-10 PCR negativity and day 30 survival. Patients who received TDF due to PCR-confirmed COVID-19 between 27.04.2021 and 31.12.2021 were included in our study. The primary outcome was considered to be 7-10 days of PCR negativity, while the secondary outcome was considered 30 -day survival after diagnosis of COVID-19. Patients who died before completing the treatment period (7-10 days) were also considered as PCR failures. Data were analyzed both in terms of intention to treat basis and in the subgroup that survived to the end of treatment. A total of 78 patients (30 women, mean age: 61.15 +/- 18.5 years) met the inclusion criteria. In the intention to treat analysis group, one -month -mortality was 44.87% (35/78) in the overall cohort. In the end of treatment analysis group, one -month -mortality was 29.5% (18/61) in the overall cohort. Day 7-10 PCR negativity was detected in 55.7% of the overall EOT cohort. Our data suggest that TDF may be an alternative salvage treatment option in antiviral unresponsive patients. We suggest evaluating TDF in well -designed controlled trials involving treatment -na & iuml;ve cases.